1106 related articles for article (PubMed ID: 31972425)
21. The oncogenic mechanisms of the Janus kinase-signal transducer and activator of transcription pathway in digestive tract tumors.
Zhao R; Hu Z; Zhang X; Huang S; Yu G; Wu Z; Yu W; Lu J; Ruan B
Cell Commun Signal; 2024 Jan; 22(1):68. PubMed ID: 38273295
[TBL] [Abstract][Full Text] [Related]
22. Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.
Mughal TI; Girnius S; Rosen ST; Kumar S; Wiestner A; Abdel-Wahab O; Kiladjian JJ; Wilson WH; Van Etten RA
Leuk Lymphoma; 2014 Sep; 55(9):1968-79. PubMed ID: 24206094
[TBL] [Abstract][Full Text] [Related]
23. Involvement of the janus kinase/signal transducer and activator of transcription signaling pathway in multiple sclerosis and the animal model of experimental autoimmune encephalomyelitis.
Benveniste EN; Liu Y; McFarland BC; Qin H
J Interferon Cytokine Res; 2014 Aug; 34(8):577-88. PubMed ID: 25084174
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic potential of JAK/STAT pathway modulation in mood disorders.
Shariq AS; Brietzke E; Rosenblat JD; Pan Z; Rong C; Ragguett RM; Park C; McIntyre RS
Rev Neurosci; 2018 Dec; 30(1):1-7. PubMed ID: 29902157
[TBL] [Abstract][Full Text] [Related]
25. Insulin-like growth factor-I receptor signal transduction and the Janus Kinase/Signal Transducer and Activator of Transcription (JAK-STAT) pathway.
Himpe E; Kooijman R
Biofactors; 2009; 35(1):76-81. PubMed ID: 19319849
[TBL] [Abstract][Full Text] [Related]
26. Targeting the JAK-STAT pathway in the treatment of 'Th2-high' severe asthma.
Vale K
Future Med Chem; 2016; 8(4):405-19. PubMed ID: 26934038
[TBL] [Abstract][Full Text] [Related]
27. The Specific Roles of JAK/STAT Signaling Pathway in Sepsis.
Cai B; Cai JP; Luo YL; Chen C; Zhang S
Inflammation; 2015 Aug; 38(4):1599-608. PubMed ID: 25676437
[TBL] [Abstract][Full Text] [Related]
28. Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease.
O'Sullivan LA; Liongue C; Lewis RS; Stephenson SE; Ward AC
Mol Immunol; 2007 Apr; 44(10):2497-506. PubMed ID: 17208301
[TBL] [Abstract][Full Text] [Related]
29. Quercetin as a JAK-STAT inhibitor: a potential role in solid tumors and neurodegenerative diseases.
Zalpoor H; Nabi-Afjadi M; Forghaniesfidvajani R; Tavakol C; Farahighasreaboonasr F; Pakizeh F; Dana VG; Seif F
Cell Mol Biol Lett; 2022 Jul; 27(1):60. PubMed ID: 35883021
[TBL] [Abstract][Full Text] [Related]
30. Targeting the interleukin-6/Jak/stat pathway in human malignancies.
Sansone P; Bromberg J
J Clin Oncol; 2012 Mar; 30(9):1005-14. PubMed ID: 22355058
[TBL] [Abstract][Full Text] [Related]
31. JAK/STAT pathway modulation: Does it work in dermatology?
Gündüz Ö
Dermatol Ther; 2019 May; 32(3):e12903. PubMed ID: 30964573
[TBL] [Abstract][Full Text] [Related]
32. JAK/STAT signaling pathway and its regulation on insect immunity.
Wei XY; Hu DC; Gao ZP; Feng CJ
Yi Chuan; 2023 Mar; 45(3):229-236. PubMed ID: 36927649
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds.
Migita K; Izumi Y; Torigoshi T; Satomura K; Izumi M; Nishino Y; Jiuchi Y; Nakamura M; Kozuru H; Nonaka F; Eguchi K; Kawakami A; Motokawa S
Clin Exp Immunol; 2013 Dec; 174(3):356-63. PubMed ID: 23968543
[TBL] [Abstract][Full Text] [Related]
34. JAK-STAT inhibitors: Immersing therapeutic approach for management of rheumatoid arthritis.
Singh S; Singh S
Int Immunopharmacol; 2020 Sep; 86():106731. PubMed ID: 32590315
[TBL] [Abstract][Full Text] [Related]
35. Targeting SOCS Proteins to Control JAK-STAT Signalling in Disease.
Durham GA; Williams JJL; Nasim MT; Palmer TM
Trends Pharmacol Sci; 2019 May; 40(5):298-308. PubMed ID: 30948191
[TBL] [Abstract][Full Text] [Related]
36. Advances in the Development of Janus Kinase Inhibitors in Inflammatory Bowel Disease: Future Prospects.
Flamant M; Rigaill J; Paul S; Roblin X
Drugs; 2017 Jul; 77(10):1057-1068. PubMed ID: 28523588
[TBL] [Abstract][Full Text] [Related]
37. Targeting the JAK-STAT pathway in autoimmune diseases and cancers: A focus on molecular mechanisms and therapeutic potential.
Tzeng HT; Chyuan IT; Lai JH
Biochem Pharmacol; 2021 Nov; 193():114760. PubMed ID: 34492272
[TBL] [Abstract][Full Text] [Related]
38. JAKs to STATs: A tantalizing therapeutic target in acute myeloid leukemia.
Venugopal S; Bar-Natan M; Mascarenhas JO
Blood Rev; 2020 Mar; 40():100634. PubMed ID: 31677846
[TBL] [Abstract][Full Text] [Related]
39. JAK/STAT pathway and molecular mechanism in bone remodeling.
Sanpaolo ER; Rotondo C; Cici D; Corrado A; Cantatore FP
Mol Biol Rep; 2020 Nov; 47(11):9087-9096. PubMed ID: 33099760
[TBL] [Abstract][Full Text] [Related]
40. JAK/STAT of all trades: linking inflammation with cancer development, tumor progression and therapy resistance.
Sabaawy HE; Ryan BM; Khiabanian H; Pine SR
Carcinogenesis; 2021 Dec; 42(12):1411-1419. PubMed ID: 34415330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]